Matthew A. Spear
2021
In 2021, Matthew A. Spear earned a total compensation of $1.6M as Former Chief Medical Officer at Poseida Therapeutics, a 168% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $159,090 |
|---|---|
| Option Awards | $1,037,890 |
| Salary | $441,917 |
| Other | $9,252 |
| Total | $1,648,149 |
Spear received $1M in option awards, accounting for 63% of the total pay in 2021.
Spear also received $159.1K in non-equity incentive plan, $441.9K in salary and $9.3K in other compensation.
Rankings
In 2021, Matthew A. Spear's compensation ranked 6,840th out of 12,415 executives tracked by ExecPay. In other words, Spear earned more than 44.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,840 out of 12,415 | 45th |
Division Manufacturing | 2,979 out of 5,505 | 46th |
Major group Chemicals And Allied Products | 1,320 out of 2,375 | 44th |
Industry group Drugs | 1,177 out of 2,096 | 44th |
Industry Biological Products, Except Diagnostic Substances | 279 out of 449 | 38th |
Source: SEC filing on April 27, 2022.
Spear's colleagues
We found three more compensation records of executives who worked with Matthew A. Spear at Poseida Therapeutics in 2021.